Vector and iBET collaborate to accelerate gene delivery platform

Virus-like particles

Vector BioPharma and the Instituto de Biologia Experimental e Tecnológica (iBET) have agreed a multi-phase collaboration to advance the technical development of Vector’s gene delivery platform. 

Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins. 

Lorenz Mayr, CEO at Vector BioPharma, said: “Collaboration with industry-leading R&D institutions and researchers in the biopharmaceutical manufacturing sector is key to accelerating the development of Vector BioPharma’s gene delivery platform as we look towards large scale and GMP manufacturing.” 

Utilising iBET’s expertise in developing integrated bioprocesses and analytical methods for the production, purification and characterisation of virus-based pharmaceuticals, the collaboration will be executed in multiple stages.  

Initially, the collaboration will seek to develop a high-throughput analytical method for full-to-empty capsid ratio quantification from both in-process and final purified samples. Monitoring the full-to-empty capsid ratio, which is a critical quality attribute of virus-based biotherapeutics, is used to determine the purity and safety of such products during the manufacturing process and at the final product stage.  

Subsequent collaboration stages will focus on the upstream process development for the large-scale manufacturing of Vector BioPharma’s virus-like particles. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free